Telos Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.4M Buy
23,234
+858
+4% +$400K 0.99% 32
2025
Q4
$10.1M Buy
22,376
+1,188
+6% +$512K 0.95% 31
2025
Q3
$8.3M Buy
21,188
+1,946
+10% +$813K 0.8% 43
2025
Q2
$8.57M Buy
19,242
+1,068
+6% +$492K 0.87% 36
2025
Q1
$8.81M Buy
18,174
+547
+3% +$255K 0.96% 30
2024
Q4
$7.1M Buy
17,627
+1,605
+10% +$744K 0.76% 44
2024
Q3
$7.45M Buy
16,022
+6
+0% +$2.88K 0.78% 43
2024
Q2
$7.51M Buy
16,016
+546
+4% +$237K 0.83% 38
2024
Q1
$6.47M Buy
15,470
+397
+3% +$168K 0.73% 45
2023
Q4
$6.13M Buy
15,073
+237
+2% +$87.6K 0.75% 44
2023
Q3
$5.16M Sell
14,836
-90
-0.6% -$31.5K 0.72% 45
2023
Q2
$5.25M Sell
14,926
-333
-2% -$112K 0.7% 50
2023
Q1
$4.81M Sell
15,259
-841
-5% -$252K 0.67% 59
2022
Q4
$4.65M Sell
16,100
-43
-0.3% -$13.1K 0.68% 57
2022
Q3
$4.67M Sell
16,143
-622
-4% -$179K 0.77% 46
2022
Q2
$4.72M Sell
16,765
-175
-1% -$46.8K 0.72% 49
2022
Q1
$4.42M Sell
16,940
-159
-0.9% -$37.7K 0.57% 64
2021
Q4
$3.75M Buy
17,099
+581
+4% +$113K 0.47% 72
2021
Q3
$3M Buy
16,518
+1,156
+8% +$226K 0.41% 80
2021
Q2
$3.1M Buy
+15,362
New +$3.21M 0.41% 80

Other funds holding VRTX

Telos Capital Management's VRTX Position: Q1 2026 in Review

Telos Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 3.8% in Q1 2026, buying an estimated $400K and bringing the position to 23,234 shares worth $10.4M. The position accounts for 0.99% of the portfolio, ranked #32.

Telos Capital Management first reported a position in VRTX in Q2 2021 and has held it in 20 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Telos Capital Management held 23,234 shares of Vertex Pharmaceuticals worth $10.4M as of Q1 2026.
  • Telos Capital Management bought 858 Vertex Pharmaceuticals shares in Q1 2026, an estimated $400K.
  • Vertex Pharmaceuticals made up 0.99% of Telos Capital Management's portfolio in Q1 2026, its #32 holding.
  • Telos Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Telos Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.